Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Appl Environ Microbiol ; 72(8): 5615-7, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16885316

RESUMEN

A human trial was carried out to assess the ileal and fecal survival of Lactobacillus casei DN-114 001 ingested in fermented milk. Survival rates were up to 51.2% in the ileum and 28.4% in the feces. The probiotic bacterium has the capacity to survive during its transit through the human gut.


Asunto(s)
Dieta , Fermentación , Tracto Gastrointestinal/microbiología , Lacticaseibacillus casei/crecimiento & desarrollo , Leche/metabolismo , Probióticos , Adulto , Animales , Recuento de Colonia Microbiana , Heces/microbiología , Femenino , Humanos , Íleon/microbiología , Lacticaseibacillus casei/aislamiento & purificación , Masculino , Leche/microbiología , Resultado del Tratamiento
2.
Br J Nutr ; 93(4): 457-69, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15946407

RESUMEN

We investigated the feasibility of increasing ursodeoxycholic acid (UDCA) in the enterohepatic circulation of pigs by administering living bacteria capable of epimerising endogenous amidated chenodeoxycholic acid (CDCA) to UDCA. We first demonstrated that combining Bifidobacterium animalis DN-173 010, as a bile salt-hydrolysing bacterium, and Clostridium absonum ATCC 27555, as a CDCA to UDCA epimerising bacterium, led to the efficient epimerisation of glyco- and tauro-CDCA in vitro, with respective UDCA yields of 55.8 (SE 2.8) and 36.6 (SE 1.5)%. This strain combination was then administered to hypercholesterolaemic pigs over a 3-week period, as two daily preprandial doses of either viable (six experimental pigs) or heat-inactivated bacteria (six controls). The main effects of treatment were on unconjugated bile acids (P=0.035) and UDCA (P<0.0001) absorbed into the portal vein, which increased 1.6-1.7- and 3.5-7.5-fold, respectively, under administration of living compared with inactivated bacteria. In bile, UDCA did not increase significantly, but the increase in biliary lithocholic acid with time in the controls was not observed in the experimental pigs (P=0.007), and the same trend was observed in faeces. All other variables (biliary lipid equilibrium, plasma lipid levels and partition of cholesterol between the different lipoprotein classes) remained unaffected by treatment throughout the duration of the experiment. In conclusion, it is feasible to increase the bioavailability of UDCA to the intestine and the liver by administering active bacteria. This may represent an interesting new probiotic activity, provided that in future it could be expressed by a safe food micro-organism.


Asunto(s)
Bacterias , Circulación Enterohepática , Hipercolesterolemia/terapia , Probióticos , Ácido Ursodesoxicólico/sangre , Administración Oral , Animales , Bifidobacterium/metabolismo , Disponibilidad Biológica , Ácido Quenodesoxicólico/metabolismo , Clostridium/metabolismo , Hipercolesterolemia/sangre , Masculino , Modelos Animales , Racemasas y Epimerasas/metabolismo , Estómago/microbiología , Porcinos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA